Genentech identifies blood as source of antitumor T cells   In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T...

An open-label, dose-escalation, U.S. Phase I trial in 38 patients with advanced metastatic solid cancers or chordoma showed that 1, 2 and 4 injections of once-monthly 2x10 8 plaque-forming units (PFUs) subcutaneous MVA-BN Brachyury for...

Bavarian Nordic began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1, 2 or 4 injections of 2x10 8 infectious units of subcutaneous MVA-BN Brachyury once monthly for 3 months in up to 28...